Medtronic to Present New Clinical Data on Vascular Interventions and Key Symposia at VEITHsymposium 2017

DUBLIN - November 13, 2017 - Medtronic plc (NYSE: MDT) today announced several noteworthy presentations of clinical studies and symposia on aortic, peripheral, endoVenous, and vascular embolization therapies at the 44th Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium), the world's largest educational meeting specializing in vascular surgical medicine in New York from November 14 - 18, 2017.

In a first-to-podium presentation, William Jordan, M.D., professor of surgery and chief, Division of Vascular Surgery and Endovascular Therapy at Emory University School of Medicine and co-principal investigator of the ANCHOR registry, will report on 12-month results from the ANCHOR Registry evaluating the FDA-approved Endurant(TM) II/IIs Stent Graft System in combination with the Heli-FX(TM) EndoAnchor System in subjects with abdominal aortic aneurysm (AAA) with aortic necks less than 10mm.

Frank R. Arko III, M.D., chief, Vascular and Endovascular surgery, professor, Cardiovascular Surgery and co-director, Aortic Institute, will present new 30-day clinical outcomes on the investigational Valiant(TM) Navion device, a minimally invasive thoracic endovascular aortic repair (TEVAR) system for patients with descending thoracic AAA disease.

"At this year's VEITHsymposium, we are thrilled to be able to feature nearly 40 different clinical presentations on our aortic, peripheral, endoVenous, and vascular embolization therapies, six of which are podium-firsts," said Jason Weidman, senior vice president and president of the Aortic & Peripheral Vascular division, which is part of the Cardiac and Vascular Group at Medtronic. "The vast amount of data being featured this week underscores our commitment to durable, consistent and safe vascular procedures, as well as industry-leading clinical rigor and data transparency."

A schedule of key data presentations and symposia appear below in chronological order in Eastern Standard Time. Some of the titles included in the presentations below may include investigational devices or uses. All presentations will be held at the New York Hilton Midtown.

Monday, November 13
1:00 p.m. - AIM Symposium: Treatment of Pelvic Reflux and Prostate Artery Embolization
Location: Gramercy West
Moderator: Ripal Gandhi, M.D.
Speaker: Shivank Bhatia, M.D.

Tuesday, November 14
6:57 a.m. - DEBATE: Not So: With Modern Endografts and Improved Techniques EVAR Outside IFUs Can Have Good Outcomes with Low Rates of Endoleaks and Sac Growth
Session 9: Grand Ballroom East, Third Floor
Presenter: Dittmar Bockler, M.D.

11:39 a.m. - For Short Necked AAAs Standard EVAR Plus Fixing with EndoAnchors is the Best Treatment for Many Patients; What Are the Limits?
Session 12: Grand Ballroom West, Third Floor
Presenter: William Jordan, M.D.

Wednesday, November 15
12:00 p.m. - Symposium: Treating Simple to Complex Femoropopliteal Lesions Through Luminal Gain and Drug-Coated Balloon Technology
Location: Medtronic Pavilion, Third Floor
Moderator: Peter Schneider, M.D.
Speakers: Gunnar Tepe, M.D., William Gray, M.D., Eric Scott, M.D.

Thursday, November 16
10:45 a.m. - Early Clinical Results and Experience with Next Generation Valiant Navion Low-Profile TEVAR Device
Session 57: Grand Ballroom West, Third Floor
Presenter: Frank R. Arko III, M.D.

12:00 p.m. - Symposium: Expanding Patient Care Options
Location: Medtronic Pavilion, Third Floor
Moderator: Ross Millner, M.D.
Speakers: David Deaton, M.D., William Jordan, M.D., Frank R. Arko III, M.D.

12:00 p.m. - Symposium: VenaSeal Closure System Panel Discussion: The Procedure, The Patients and Your Practice
Location: Gramercy
Moderator: Brian Ferris, M.D.
Speakers: Kathleen Gibson, M.D., Joseph Ricotta, M.D., Manjit Gohel, M.D.

3:25 - 4:12 p.m. - Concurrent EndoAnchor Sessions: Indication and Value, EndoAnchors with TEVAR
Session 61: Grand Ballroom West, Third Floor
Moderators: Luis Sanchez, M.D., William Jordan, M.D.

In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

About VEITHsymposium

Now in its 44th year, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Press will receive complimentary registration. Please visit or contact Pauline T. Mayer at +1-561-316-3330.

About Medtronic
Medtronic plc ( headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.



Julia Baron
Public Relations

Ryan Weispfenning
Investor Relations